ArticleCancer medicine2019
Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Clinicopathological Features and Prognostic-Related Risk Factors of Gastric Signet Ring Cell Carcinoma: A Meta-Analysis.Computational and mathematical methods in medicine · 2022Pooled it
- Prognostic factors and the role of chemotherapy in patients with pT3N0M0 gastric cancer: a propensity score matching analysis based on the SEER database.Discover oncology · 2025Article
- Who are optimal candidates for primary tumor resection in patients with metastatic gastric adenocarcinoma? A population-based study.PloS one · 2024Article
- Gastrointestinal signet ring cell malignancy: current advancement and future prospects.Investigational new drugs · 2023Review
- Clinicopathological characteristics and prognosis of gastric signet ring cell carcinoma.World journal of clinical cases · 2022Article
- Survival benefit of surgical resection for stage IV gastric cancer: A SEER-based propensity score-matched analysis.Frontiers in surgery · 2022Article
- Characteristics and Predictors of Long-Time Survivors in Non-Metastatic Gastric Signet Ring Cell Carcinoma: A Large Population-Based Study.International journal of general medicine · 2022Article
- Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma.Journal of oncology · 2022Article
- Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the gallbladder.BMC gastroenterology · 2021Article
- Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.Histology and histopathology · 2021Review
- Brain Metastasis in Patients with Small Cell Lung Cancer.International journal of general medicine · 2021Article
- Estimating the treatment effect in patients with gastric cancer in the presence of noncompliance.Gastroenterology and hepatology from bed to bench · 2021Article
- Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy.Cancer medicine · 2020Article
- Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges.Cancer management and research · 2020Review
- Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.Theranostics · 2020Article
- Survival benefit of palliative gastrectomy followed by chemotherapy in stage IV gastric signet ring cell carcinoma patients: A large population-based study.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundStage IV gastric signet ring cell carcinoma (SRCC) is a type of malignant gastric cancer (GC) with poorer survival compared to metastatic non-SRCC gastric cancer (NOS). However, chemotherapy alone was unable to maintain long-term survival. This study aimed to evaluate survival benefit of palliative gastrectomy plus chemotherapy (PG+C) for metastatic gastric SRCC.
methodsWe obtained data on gastric cancer patients between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Statistical methods included χ
resultsAmong 27 240 gastric cancer patients included, 4638 (17.03%) were SRCC patients. The proportion of patients with younger age, female gender, poorly differentiated grade and M1 stage was higher in SRCC than in NOS (P < .001). Multivariate analysis revealed that multiple metastatic sites (HR = 1.39, 95% CI: 1.14-1.69, P = .001) was associated with increased mortality risk in metastatic SRCC. Median survival time was improved in metastatic SRCC receiving PG+C compared to PG/C alone (13 vs 7 months, P < .001). Notably, in subgroup analysis, 13 of 17 groups of metastatic SRCC patients with PG+C had prolonged overall survival compared to chemotherapy alone, especially for those with only one metastatic site (HR = 0.61, 95% CI: 0.51-0.73, P < .001).
conclusionsOur results suggested that there exists at least a selective group of stage IV gastric SRCC patients, who could benefit from palliative gastrectomy followed by chemotherapy compared to chemotherapy alone. Further prospective trials are needed to support our conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.